Listonstreetpulse.com announces that Arrayit Corporation (OTC: ARYC) has shipped its proprietary life sciences products to search engine giant Google Inc. (NASDAQ: GOOG). Arrayit is a microarray technology leader offering platforms, instruments, tools, kits and reagents to empower human genome discoveries including the ability to decipher all 6,000 human diseases.
Genomic and proteomic information generated using the Arrayit platform benefits from intensive computational capacity and advanced mathematical algorithms analogous to those used for Internet search. This creates a natural fit between the Arrayit Microarray Platform and Google.
In 2009, Google had invested $7 million in the consumer genetics firm 23andMe, which uses microarray technology to deliver health, disease and ancestry information to the public. Earlier this year, Arrayit proposed a consumer testing opportunity to Facebook (NASDAQ: FB), further underscoring the perceived synergy between life sciences companies and Internet search and social networking.
In 2012, Google reported $50.1 billion in revenue, $10.7 billion in net income, and cash assets of $14.7 billion. Arrayit will report the revenue and earnings from the Google sale in the fourth quarter of the year.
To read more about ARYC and subscribe to a monthly update, CEO interview etc, please click here – http://www.listonstreetpulse.com/tag/ARYC/
About Arrayit Corporation
Arrayit Corporation is a Sunnyvale, California-based company leading and empowering the genetic, research, pharmaceutical, and diagnostic communities through the discovery, development, and manufacture of proprietary life science technologies and consumables for disease prevention, treatment and cure. The company’s innovative products and services help scientists and clinicians explore the human genome as well as the genomes of plants and animals. Arrayit’s products are used by every major research center in the world.
About Liston Street Pulse
Liston Street Pulse is a leading provider of financial research. The company has significant expertise in U.S. listed small cap and micro-cap stocks. Over the years, Liston Street Pulse’s original and unbiased analysis has helped the investor community immensely.
